pentamidine has been researched along with paromomycin in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.33) | 18.7374 |
| 1990's | 4 (16.67) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 9 (37.50) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Boykin, DW; Hall, JE; Kyle, DE; Liu, Q; Madhubala, R; Mandal, S; Munde, M; Pandharkar, T; Parman, T; Riccio, E; Srivastava, A; Stephens, CE; Sweat, JM; Tidwell, RR; Wang, MZ; Werbovetz, KA; Wilson, WD; Zhu, X | 1 |
| Carvalho, L; Castanys, S; Gamarro, F; Manzano, JI; Pérez-Victoria, JM | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chan, KF; Chan, TH; Chow, LM; Wong, IL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Croft, SL; Frommel, D; Gebre-Hiwot, A; Tadesse, G | 1 |
| Hosseini, J; Swan, JC; Zierdt, CH | 1 |
| Abu-Elheiga, L; Bachrach, U; Schnur, LF | 1 |
| Croft, SL; Lawrence, F; Maarouf, M; Robert-Gero, M | 1 |
| Craciunescu, DG; Loiseau, PM; Mbongo, N; Robert-Gero, M | 1 |
| Ballet, JJ; Brasseur, P; Delaunay, A; Favennec, L; Gargala, G | 1 |
| Sundar, S | 2 |
| Berman, J | 1 |
| Kumar, A; Sundar, S | 1 |
| Minodier, P; Parola, P | 1 |
| Amato, VS; Neto, VA; Nicodemo, AC; Siqueira, AM; Tuon, FF | 1 |
| Amato Neto, V; Amato, VS; Graf, ME; Nicodemo, AC; Siqueira, AM; Tuon, FF | 1 |
| Calza, L; Manfredi, R; Marinacci, G; Passarini, B | 1 |
| Kumar, M; Singh, N; Singh, RK | 1 |
| de Paula, E; Giorgio, S; Ortega, V | 1 |
| Ajata, A; Berman, J; Luque, C; Paz, D; Rivero, D; Soto, J; Soto, P; Tintaya, C | 1 |
| Castro, MDM; Cossio, A; Desai, MM; Prieto, MD; Uribe-Restrepo, AF | 1 |
| Carneiro, SP; Registre, C; Rubio, KTS; Santos, ODH; Soares, RDOA | 1 |
9 review(s) available for pentamidine and paromomycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Treatment of visceral leishmaniasis.
Topics: Administration, Oral; Amphotericin B; Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Paromomycin; Pentamidine | 2001 |
Current treatment approaches to leishmaniasis.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Clinical Trials as Topic; Fluconazole; Humans; Leishmaniasis; Paromomycin; Pentamidine; Phosphorylcholine | 2003 |
Cutaneous leishmaniasis treatment.
Topics: Administration, Cutaneous; Administration, Oral; Aminoquinolines; Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Humans; Imiquimod; Injections, Intralesional; Injections, Intramuscular; Leishmaniasis, Cutaneous; Paromomycin; Pentamidine; Phosphorylcholine | 2007 |
Treatment of mucosal leishmaniasis in Latin America: systematic review.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Humans; Itraconazole; Latin America; Leishmania; Leishmaniasis, Mucocutaneous; Meglumine; Paromomycin; Pentamidine | 2007 |
Treatment of New World cutaneous leishmaniasis--a systematic review with a meta-analysis.
Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Developing Countries; Endemic Diseases; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Paromomycin; Pentamidine | 2008 |
Leishmaniasis: current status of available drugs and new potential drug targets.
Topics: Aminoquinolines; Amphotericin B; Antigens, Protozoan; Antimony Sodium Gluconate; Antiprotozoal Agents; Caspase Inhibitors; Cyclin-Dependent Kinases; Drug Discovery; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Leishmaniasis; Macrophages; Microbodies; Mitogen-Activated Protein Kinase Kinases; Paromomycin; Pentamidine; Phosphorylcholine; Polyamines; Protease Inhibitors; Sterols; Sulfhydryl Compounds; Topoisomerase Inhibitors | 2012 |
Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Compounding; Drug Delivery Systems; Drug Liberation; Humans; Leishmaniasis; Liposomes; Nanoparticles; Paromomycin; Particle Size; Pentamidine; Phosphorylcholine; Surface Properties | 2017 |
A Systematic Review of Drug-Carrying Nanosystems Used in the Treatment of Leishmaniasis.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis; Paromomycin; Pentamidine; Pharmaceutical Preparations | 2023 |
1 trial(s) available for pentamidine and paromomycin
| Article | Year |
|---|---|
Topical 15% Paromomycin-Aquaphilic for Bolivian Leishmania braziliensis Cutaneous Leishmaniasis: A Randomized, Placebo-controlled Trial.
Topics: Administration, Topical; Adult; Antiprotozoal Agents; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Paromomycin; Pentamidine; Young Adult | 2019 |
14 other study(ies) available for pentamidine and paromomycin
| Article | Year |
|---|---|
Novel arylimidamides for treatment of visceral leishmaniasis.
Topics: Amidines; Animals; Antiprotozoal Agents; Biological Availability; Cricetinae; Disease Models, Animal; Drug Discovery; Female; Furans; Humans; In Vitro Techniques; Leishmania donovani; Leishmania major; Leishmania mexicana; Leishmaniasis, Visceral; Liver; Mesocricetus; Mice; Mice, Inbred BALB C; Microsomes, Liver; Mutagenicity Tests; Parasitemia; Parasitic Sensitivity Tests; Spleen; Tissue Distribution | 2010 |
Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.
Topics: Adenosine Triphosphate; Aminoquinolines; Antiprotozoal Agents; Drug Resistance; Glycolysis; Leishmania major; Pyruvate Kinase | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Flavonoid dimers as novel, potent antileishmanial agents.
Topics: Amines; Animals; Antiprotozoal Agents; Cell Line; Dimerization; Drug Resistance; Flavonoids; Leishmania; Macrophages, Peritoneal; Mice; Polyethylene Glycols; Structure-Activity Relationship | 2012 |
An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1.
Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Evaluation, Preclinical; Humans; Leishmania; Leishmania donovani; Leukemia, Monocytic, Acute; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Paromomycin; Pentamidine; Species Specificity; Tumor Cells, Cultured | 1992 |
In vitro response of Blastocystis hominis to antiprotozoal drugs.
Topics: Animals; Antiprotozoal Agents; Emetine; Eukaryota; Furans; Furazolidone; Metronidazole; Paromomycin; Pentamidine; Quinolines; Sulfamethoxazole; Trimethoprim | 1983 |
Leishmania tropica major: effect of paromomycin and pentamidine on polyamine levels in the skin of normal and infected mice.
Topics: Adenosylmethionine Decarboxylase; Amidines; Animals; Drug Evaluation, Preclinical; Leishmaniasis; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Ornithine Decarboxylase; Paromomycin; Pentamidine; Polyamines; Putrescine; Skin; Spermidine; Spermine; Time Factors | 1983 |
Ribosomes of Leishmania are a target for the aminoglycosides.
Topics: Animals; Centrifugation, Density Gradient; Cytoplasm; Framycetin; Leishmania donovani; Leishmania tropica; Magnesium; Mitochondria; Paromomycin; Pentamidine; Ribosomes; Spermidine | 1995 |
Synergistic effect of Ir-(COT)-pentamidine alizarin red and pentamidine, amphotericin B, and paromomycin on Leishmania donovani.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Synergism; Female; Iridium; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Mice; Mice, Inbred BALB C; Organometallic Compounds; Paromomycin; Pentamidine; Random Allocation | 1998 |
Enzyme immunoassay detection of Cryptosporidium parvum inhibition by sinefungin in sporozoite infected HCT-8 enterocytic cells.
Topics: Adenosine; Amebicides; Animals; Antiprotozoal Agents; Cell Line; Cryptosporidium parvum; Dose-Response Relationship, Drug; Fluorescent Antibody Technique, Indirect; Humans; Immunoenzyme Techniques; Parasite Egg Count; Paromomycin; Pentamidine; Rats; Rats, Sprague-Dawley; Time Factors | 1999 |
Drug resistance in Indian visceral leishmaniasis.
Topics: Aminoquinolines; Amphotericin B; Antimony; Antiprotozoal Agents; Dose-Response Relationship, Drug; Drug Resistance; Geography; History, 20th Century; History, 21st Century; Humans; India; Leishmaniasis, Visceral; Paromomycin; Pentamidine; Phosphorylcholine; Treatment Outcome | 2001 |
Challenges in the management of visceral leishmaniasis.
Topics: Amebicides; Amphotericin B; Antimony Sodium Gluconate; Antiparasitic Agents; Antiprotozoal Agents; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique, Indirect; Humans; Immunoglobulin G; Leishmaniasis, Visceral; Paromomycin; Pentamidine; Phosphorylcholine | 2005 |
Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine a
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Drug Carriers; HIV Infections; Humans; Leishmaniasis, Visceral; Liposomes; Male; Paromomycin; Pentamidine; Treatment Failure | 2008 |
Eligibility for Local Therapies in Adolescents and Adults with Cutaneous Leishmaniasis from Southwestern Colombia: A Cross-Sectional Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimony; Antiprotozoal Agents; Child; Colombia; Cross-Sectional Studies; Cryotherapy; Female; Humans; Hyperthermia, Induced; Leishmania braziliensis; Leishmania guyanensis; Leishmaniasis, Cutaneous; Male; Middle Aged; Paromomycin; Pentamidine; Practice Guidelines as Topic; Severity of Illness Index | 2019 |